Doximity's AI Ascent: Powering Physician Productivity and Profitability in its Third Act (NYSE:DOCS) - DOCS Stock Research Report

## Executive Summary / Key Takeaways * AI as the "Third Act": Doximity is strategically investing heavily in AI, positioning its Doximity AI Scribe, Doximity GPT, and the newly acquired Pathway Medical's clinical reference as a synergistic "third act" to transform physician workflow and clinical decision-making, aiming for an opportunity potentially larger than its existing core businesses. * Robust Financial Performance & Outlook: The company delivered a strong Q1 FY26 with 15% year-over-year revenue growth to $145.9 million and an impressive 55% adjusted EBITDA margin, exceeding guidance. Full-year FY26 guidance projects 11% revenue growth to $628-$636 million and a 55% adjusted EBITDA margin, reflecting broad-based strength and strategic investments. * Deepening Engagement & Monetization: Doximity continues to see record physician engagement across its newsfeed (over 1 million active prescribers) and workflow tools (630,000 active prescribers), with AI tools growing over 5x year-over-year. New point-of-care and formulary products are driving significant pharma sales, and the client portal is enhancing customer ROI and upsell opportunities. * Strategic Competitive Moat: Doximity's competitive advantage stems from its extensive network, 10+ years of first-party data, and a diversified, high-ROI platform. Its AI offerings, particularly Pathway's 96% USMLE score, demonstrate a technological edge that is attracting clients away from less effective programmatic advertising. * Prudent Growth Amidst Uncertainty: Despite strong performance, management maintains a measured approach to its full-year guidance, factoring in continued policy and macroeconomic uncertainties, particularly within the pharma and health system sectors, while still expecting its pharma business to grow at roughly twice the market rate. ## Doximity's Digital Dominion: Forging the Future of Healthcare with AI Doximity, Inc. ($DOCS) has firmly established itself as the leading digital platform for U.S. medical professionals, a position cultivated since its inception in 2010. Its mission is clear: to empower physicians to be more productive and deliver superior patient care. This foundational principle has guided Doximity through its "first act" – a robust newsfeed and LinkedIn-style professional networking – and its "second act" – a comprehensive suite of workflow tools including telehealth, fax, and scheduling. Today, Doximity serves over 80% of U.S. physicians, spanning all specialties and states, making it an indispensable part of the modern medical practice. The company's strategic evolution is now squarely focused on its "third act": artificial intelligence. This pivotal shift aims to address the pervasive challenges of physician burnout and information overload by integrating AI directly into the clinical workflow. By leveraging its deep understanding of physician needs and a decade of proprietary data, Doximity is building a synergistic AI suite designed to save time, enhance decision-making, and ultimately improve patient outcomes. ## Technological Edge: The AI-Powered Third Act Doximity's core technology is its integrated digital platform, which has consistently driven high engagement. The newsfeed, a cornerstone of its "first act," provides personalized medical news and research, reaching over 1 million quarterly active prescribers in Q1 FY26. This product saw double-digit percentage growth in articles read or tapped, including a more than 30% year-over-year increase in Q4 FY25, partly due to generative AI rewriting headlines for better digestibility. The "second act" of workflow tools, including the Doximity Dialer, secure messaging, and on-call scheduling, also achieved record highs, with 630,000 unique active prescribers in Q1 FY26. The Doximity Dialer, initially a free product, has evolved into an enterprise solution, now serving over 200 health systems and used by approximately 45% of all U.S. physicians. These tools are designed for daily, "9 to 5" use, making them highly sticky. The "third act" is where Doximity is making its most significant technological strides. Its AI tools are growing the fastest, up more than 5x year-over-year in Q1 FY26, and generated 1.8 million prompts in Q3 FY25, a 60% quarter-over-quarter increase. This AI suite includes: * Doximity AI Scribe: Launched in Q1 FY26, this HIPAA-compliant ambient notetaking tool was beta-tested by over 10,000 physicians, PAs, and NPs. It aims to reduce the "pajama time" doctors spend on notes (an average of 1.5 hours nightly) by providing a free, physician-controlled, and private solution. Over 75% of Scribe users return weekly, highlighting its stickiness. The cost of medical-grade AI transcription has dramatically decreased, now in the "pennies per visit camp," making this free offering sustainable. Future plans include integrating Scribe directly into telehealth tools for a seamless virtual visit and note-taking experience. * Pathway Medical Acquisition: In July 2025, Doximity acquired Pathway Medical Inc. for $26 million in cash and up to $37 million in equity grants. Pathway, a 6-person, 7-year-old Montreal startup, specializes in AI clinical reference. Its team, comprising physicians trained at top institutions, painstakingly built one of the "best and largest medical AI data sets around," covering guidelines, drugs, journals, and landmark trials. This "corpus" is cross-linked for industry-leading accuracy and speed, understanding complex drug interactions and scoring medical evidence strength. Pathway's AI model scored an impressive 96% on the U.S. medical licensing exam, outperforming competitors. * Doximity GPT: Pathway's robust corpus and fine-tuned AI have been integrated into Doximity's free Doximity GPT product, which was launched just three months after ChatGPT and is HIPAA-compliant. This tool helps doctors write letters, prior authorizations, and patient education materials. The "so what" for investors is profound. Management believes this AI suite could be an opportunity "as big or perhaps even bigger than our first 2 acts," fundamentally addressing the "core of search" for physicians. By automating administrative tasks and providing instant, accurate clinical answers, Doximity aims to save doctors "around thirteen hours a week," driving unparalleled engagement and creating new monetization avenues, similar to how the Dialer product transitioned from free to enterprise. ## Financial Strength and Strategic Execution Doximity's financial performance in Q1 fiscal year 2026 underscores its operational effectiveness and strategic momentum. The company reported revenue of $145.9 million, a 15% increase year-over-year, surpassing the high end of its guidance. This growth was primarily fueled by a $17.9 million increase in subscription revenue, with $4.8 million from new customers and $13.1 million from the expansion of existing clients. Notably, average revenue per existing Marketing Solutions customer increased by approximately 14%. Subscription revenue constituted approximately 94% of the total.

Loading interactive chart...

Profitability remains a hallmark of Doximity's business model. Q1 FY26 adjusted EBITDA reached $79.8 million, translating to a robust 55% adjusted EBITDA margin, up from 52% in the prior year period. This strong bottom-line performance, with adjusted EBITDA growing 21% year-over-year, reflects the inherent efficiency of the platform.

Loading interactive chart...

Doximity's capital allocation strategy includes share repurchases, with $122.3 million worth of shares repurchased in Q1 FY26 at an average price of $53.99. The company has $302 million remaining in its existing repurchase program, viewing these buybacks as a valuable use of incremental cash. Looking ahead, free cash flow is expected to benefit from a new tax law reversing the need to capitalize R&D, projecting a cash tax rate of 10% to 15% starting in FY26.

Loading interactive chart...

Free cash flow also saw significant growth, increasing 52% year-over-year to $60.1 million. The company ended the quarter with a strong liquidity position, holding $841 million in cash, cash equivalents, and marketable securities.

Loading interactive chart...

## Competitive Landscape and Market Positioning Doximity operates in a dynamic healthcare technology market, but its competitive positioning is exceptionally strong. The company's diversified platform, encompassing news, networking, and workflow tools, creates a powerful ecosystem that differentiates it from point solutions. Its decade of first-party data provides an unparalleled ability to personalize content and services, making its newsfeed a trusted source "without a lot of the noise" found on other social media. In the competitive arena, Doximity is demonstrably gaining market share. Management noted that clients who "tried out and experiment[ed] more in the programmatic space" found those experiments "didn't work" to the same level of return as Doximity's programs. This "flight to quality" is a significant tailwind, as clients increasingly lean into "endemic" platforms that deliver proven ROI. The company's AI offerings further solidify its moat; Pathway's 96% USMLE score, for instance, positions Doximity's clinical AI as a leader, outperforming competitors in accuracy. The client portal is a critical strategic initiative, reducing friction for pharma clients and agencies. It provides real-time ROI insights and program expansion recommendations, driving favorable purchasing decisions. This has led to over 100% year-over-year bookings growth for SMB customers in Q1 FY26 through agency partnerships, which have already generated over $5 million in new business. This approach allows Doximity to expand its reach efficiently, leveraging agencies as "key portal allies" rather than directly competing in the SMB self-service market. ## Outlook and Risks Doximity's outlook for fiscal year 2026 reflects a blend of strong internal momentum and a prudent approach to external uncertainties. For Q2 FY26, the company expects revenue between $157 million and $158 million (15% growth at midpoint) and adjusted EBITDA of $87 million to $88 million (56% margin). For the full fiscal year 2026, revenue is projected to be $628 million to $636 million (11% growth at midpoint), with adjusted EBITDA in the range of $341 million to $349 million (55% margin). This increased outlook is driven by broad-based strength, particularly a promising start to the upsell season for pharma customers, fueled by an expanded commercial product portfolio and the client portal. However, management is taking a "measured approach" to the back half of the year, acknowledging that Q1 is the smallest bookings quarter and not extrapolating its outperformance. The pharma HCP digital market is expected to grow 5% to 7%, but Doximity's guidance assumes the lower end of this range due to "continued policy uncertainty" and macroeconomic factors. Despite this cautious market view, Doximity anticipates its pharma business will grow at roughly twice the market rate, driven by continued share gains. Key risks include ongoing policy uncertainty, particularly regarding potential changes like a DTC advertising ban, which could create headwinds or tailwinds for the pharma industry. Macroeconomic uncertainty also poses a risk, though Doximity's high-ROI offerings position it favorably in efficiency-focused environments. The company is also involved in securities and shareholder derivative lawsuits, alleging misrepresentation of user count and engagement rates, among other claims. While Doximity intends to vigorously defend these actions, the outcome and potential loss remain unpredictable. ## Conclusion Doximity is executing a compelling growth narrative, transitioning from its established digital platform to an AI-powered future. Its "third act" of AI-driven workflow and clinical reference tools, bolstered by the strategic acquisition of Pathway Medical, promises to deepen physician engagement and unlock significant new monetization opportunities. The company's robust financial performance, characterized by strong revenue growth, high profitability, and efficient cash flow generation, provides a solid foundation for these ambitious investments. Doximity's competitive advantages, rooted in its extensive network, proprietary data, and proven ROI, are enabling it to capture market share in a digital-first healthcare landscape. While external policy and macroeconomic uncertainties warrant a cautious outlook, the company's strategic focus on technological leadership and client value positions it for sustained growth. Investors should closely monitor the continued adoption and monetization of Doximity's AI suite and the expansion of its client portal, as these initiatives are critical to realizing the full potential of its "third act" and solidifying its long-term market leadership.